VIDEO: Highlights in non-Hodgkin lymphoma from ASCO 2023

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So in the broader field of NHL, I think that there's a lot of very promising work that is ongoing. Speaking of the bispecific antibodies, which we see activity in large cell lymphoma, we're learning more about their role in other forms of non-Hodgkin lymphoma as well. And we saw updated data at ASCO for combinations with epcoritamab (Epkinly; Genmab, AbbVie) in combination with rituximab-based treatment for patients with relapsed follicular lymphoma, establishing this combination approach as safe and active and one certainly worthy of further exploration.

We saw updated data in mantle cell lymphoma looking at real-world evidence using brexucabtagene autoleucel, brexu-cel (Tecartus, Kite Pharma/Gilead Sciences), which is the FDA-approved CAR T-cell therapy for mantle cell lymphoma. Seeing that even in a real-world patient population, more heavily pretreated, less stringently screened, that the activity and safety profile of brexu-cel really did mirror that of the ZUMA-2 trial, which led to that drug's approval.